To examine the impact of the addition of ruxolitinib to UCB-Tregs on the immune cell compartment of SLE-PBMCs, CD4+ T, CD4+CD25+CD127low Treg+, CD4+CD8+ T, CD8+ T, CD19+ B, CD56+ NK cells, and CD14+ monocytes were gated (Supplementary Figure S1). This evidence concerns the gene CD19 and systemic lupus erythematosus.